BillionaireNet
Khorakiwala
Habil Khorakiwala
Rank #2750
INDIAHealthcarepharmaceuticals

Habil Khorakiwala

Net Worth
$1.259B
+1.35% (24h)
Habil Khorakiwala, born in 1942, is the founder and chairman of Wockhardt, a leading Indian multinational pharmaceutical and biotechnology company. With an estimated net worth of $1.2 billion as of 2024, Khorakiwala's wealth stems from his pioneering role in the pharmaceuticals industry. His career began in 1967 when he transformed his father's Worli Chemical Works into Wockhardt, which has since become a global enterprise with a strong presence in the generic drugs, biopharmaceuticals, and healthcare sectors. Khorakiwala's leadership has been marked by strategic acquisitions and a focus on research and development, driving Wockhardt to become a key player in the global healthcare market.

The Full Dossier

Early Life

Habil Khorakiwala was born in Bombay (now Mumbai) in 1942 into a Dawoodi Bohra family. His father, Fakhruddin T. Khorakiwala, founded India's first departmental store, Akbarallys. Habil's early education took place in Mumbai, and he later pursued a degree in pharmacy from L.M. College in Ahmedabad. He furthered his education with a Master of Science in Pharmaceutical Science from Purdue University, USA, and an Advanced Management Programme at Harvard Business School.

Rise to Success

In 1967, Habil Khorakiwala took over his father's Worli Chemical Works, a small firm at the time. Under his leadership, the company was transformed into Wockhardt, a prominent name in the pharmaceutical industry. Wockhardt expanded significantly through strategic acquisitions and a focus on research and development. Wockhardt has manufacturing facilities across India, the UK, Ireland, France, and the US. His leadership resulted in Wockhardt emerging as a leading pharmaceutical and biotechnology conglomerate, driven by research and strategic thinking on a global scale.

Key Business Strategies

Khorakiwala's business strategies centered on innovation, research, and strategic acquisitions. The company focused on developing generic drugs, biopharmaceuticals, and vaccines. Wockhardt was the first company outside the US and Europe to manufacture recombinant human insulin. The company has also ventured into biotechnology, launching notable products like PROXYVON and BIOVAC-B. Furthermore, under his leadership, Wockhardt has been a strong advocate for 'Customer Focused' operations, which has contributed to its growth.

Philanthropy

Khorakiwala established the Wockhardt Foundation, which has impacted millions of lives through various medical and social programs. His commitment extends to providing healthcare access to underserved communities through mobile health clinics.

Career Timeline

2014

Appointed Chancellor

Appointed as the Chancellor of Jamia Hamdard University.

2010

Received Honorary Doctorate

Awarded an honorary Doctor of Pharmacy degree from Purdue University.

1972

Launched PROXYVON

Launched the first combination formulation in pain management in India.

1967

Founded Wockhardt Limited

Transformed Worli Chemical Works into a leading pharmaceutical company.

Philanthropic Impact

HealthcareUndisclosed

Wockhardt Foundation

Runs mobile healthcare vans in 10 Indian states.

Wealth Trajectory